<div id="readability-page-1"><div><p>With a price-to-earnings (or &#34;P/E&#34;) ratio of 8.4x <strong>Sinopharm Group Co. Ltd.</strong> (HKG:1099) may be sending bullish signals at the moment, given that almost half of all companies in Hong Kong have P/E ratios greater than 13x and even P/E's higher than 26x are not unusual.  Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/E.</p> <p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p> <p> Sinopharm Group could be doing better as its earnings have been going backwards lately while most other companies have been seeing positive earnings growth.   The P/E is probably low because investors think this poor earnings performance isn't going to get any better.  If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.    </p><p><span> Check out our latest analysis for Sinopharm Group </span></p><figure><img height="650" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62494979-pe-multiple-vs-industry-1-dark-2/1771280446869?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1640" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62494979-pe-multiple-vs-industry-1-dark-2/1771280446869"/><figcaption>SEHK:1099 Price to Earnings Ratio vs Industry February 16th 2026</figcaption></figure><p> Want the full picture on analyst estimates for the company? Then our <strong>free </strong>report on Sinopharm Group will help you uncover what's on the horizon.  </p><h2> Is There Any Growth For Sinopharm Group?  </h2><p> The only time you'd be truly comfortable seeing a P/E as low as Sinopharm Group's is when the company's growth is on track to lag the market.  </p><p> Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 14%.   This means it has also seen a slide in earnings over the longer-term as EPS is down 11% in total over the last three years.  So unfortunately, we have to acknowledge that the company has not done a great job of growing earnings over that time.   </p> <p> Turning to the outlook, the next year should generate growth of 14%  as estimated by the analysts watching the company.  With the market predicted to deliver 20% growth , the company is positioned for a weaker earnings result. </p><p> With this information, we can see why Sinopharm Group is trading at a P/E lower than the market.  Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.  </p> <h2> The Final Word </h2><p> Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects. </p><p> We've established that Sinopharm Group maintains its low P/E on the weakness of its forecast growth being lower than the wider market, as expected.  At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio.  It's hard to see the share price rising strongly in the near future under these circumstances.     </p><p> Before you settle on your opinion, we've discovered <strong>1 warning sign for Sinopharm Group</strong> that you should be aware of.  </p><p> Of course, <strong>you might find a fantastic investment by looking at a few good candidates.</strong> So take a peek at this <strong>free</strong> list of companies with a strong growth track record, trading on a low P/E.  </p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

600511

516500

516820

<p>Sinopharm Group Co. Ltd. (HKG:1099) has a low P/E ratio of 8.4x, indicating potential investor caution due to declining earnings. The company's EPS fell by 14% last year and 11% over three years, leading to a forecasted growth of only 14% next year, below the market's 20%. This suggests that investors are not optimistic about future earnings, resulting in a low P/E. Analysts believe the share price may not rise significantly in the near future, and there is one warning sign to consider before investing.</p>

Simplywall

SINOPHARM(CNCM LTD)

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Sinopharm Accord

SINOPHARM

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal 800 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng Health Care ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Sinopharm Group Co. Ltd.'s (HKG:1099) Low P/E No Reason For Excitement